Nov 08, 2025 • GlobeNewswire
NEUTRAL
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I ( V122I ) Populations
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: ...
Nov 04, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
BridgeBio to Participate in November Investor Conferences
PALO ALTO, Calif., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following ...
Nov 04, 2025 • Benzinga
NEUTRAL
BridgeBio to Participate in November Investor Conferences - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following ...
Nov 03, 2025 • GlobeNewswire
NEUTRAL
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I ( V122I ) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
PALO ALTO, Calif., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart ...
Nov 03, 2025 • Benzinga
NEUTRAL
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I ( V122I ) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart ...
Oct 29, 2025 • Zacks Commentary
NEUTRAL
BridgeBio Pharma ( BBIO ) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -7.95% and +14.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?